Business Description
Organovo Holdings Inc
NAICS : 541714
SIC : 2836
ISIN : US68620A1043
Description
Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.53 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.24 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -57.08 | |||||
| Beneish M-Score | -4.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -50.1 | |||||
| 3-Year EBITDA Growth Rate | 13.9 | |||||
| 3-Year EPS without NRI Growth Rate | 11.9 | |||||
| 3-Year FCF Growth Rate | 13.8 | |||||
| 3-Year Book Growth Rate | -24.5 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.55 | |||||
| 9-Day RSI | 48.05 | |||||
| 14-Day RSI | 47.6 | |||||
| 6-1 Month Momentum % | -28.23 | |||||
| 12-1 Month Momentum % | -45.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.67 | |||||
| Quick Ratio | 3.67 | |||||
| Cash Ratio | 3.11 | |||||
| Days Sales Outstanding | 140.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.1 | |||||
| Shareholder Yield % | 3.56 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -8169.01 | |||||
| Net Margin % | -7886.36 | |||||
| FCF Margin % | -6991.32 | |||||
| ROE % | -149.03 | |||||
| ROA % | -119 | |||||
| ROIC % | -517.48 | |||||
| ROC (Joel Greenblatt) % | -819.41 | |||||
| ROCE % | -141.06 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 32.79 | |||||
| PB Ratio | 1.48 | |||||
| Price-to-Tangible-Book | 1.48 | |||||
| EV-to-EBIT | -0.38 | |||||
| EV-to-EBITDA | -0.38 | |||||
| EV-to-Revenue | 30.84 | |||||
| EV-to-FCF | -0.42 | |||||
| Price-to-Net-Current-Asset-Value | 2.58 | |||||
| Price-to-Net-Cash | 3.58 | |||||
| Earnings Yield (Greenblatt) % | -263.16 | |||||
| FCF Yield % | -159.16 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers